Regulus Appoints VP, Clinical Development
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics Inc., a biopharmaceutical company developing innovative medicines targeting microRNAs, has appointed Dr. Michael Huang vice-president of clinical development. At Regulus, Huang will be responsible for leading the company's global clinical operations and medical affairs and will serve as a key member of the executive leadership team. Most recently, Huang was vice-president of clinical development at Auspex Pharmaceuticals, Inc. (acquired by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders.